Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

锡克 免疫系统 医学 癌症研究 免疫学 药理学 B细胞 自身免疫性疾病 受体 酪氨酸激酶 抗体 内科学
作者
Yu Cai,Jianlin He,Zhipeng Wu,Weigang He,Xiaoming Dai,Yan Xu,Min Cheng,Na Yang,Yongxin Ren,Guanglin Wang,Jian Wang,Yang Sai,Hong Jia,Guangxiu Dai,Xiong Li,Weiguo Su
出处
期刊:Journal of Pharmacology and Experimental Therapeutics [American Society for Pharmacology and Experimental Therapeutics]
卷期号:388 (1): 156-170 被引量:14
标识
DOI:10.1124/jpet.123.001752
摘要

Spleen tyrosine kinase (Syk) is an intracellular tyrosine kinase involved in the signal transduction in immune cells mainly. Its aberrant regulation is associated with diversified allergic disorders, autoimmune diseases and B cell malignancies. Therefore, inhibition of Syk is considered a reasonable approach to treat autoimmune/inflammatory diseases and B cell malignancies. Here we described the preclinical characterization of sovleplenib (HMPL-523), a novel, highly potent and selective, oral Syk inhibitor, in several rodent autoimmune disease models. Sovleplenib potently inhibited Syk activity in a recombinant enzymatic assay and Syk-dependent cellular functions in various immune cell lines and human whole blood in vitro. Furthermore, sovleplenib, by oral administration, demonstrated strong in vivo efficacies in murine models of immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and chronic graft-versus-host disease (cGVHD), and a rat model of collagen induced arthritis (CIA) respectively, in a dose-dependent manner. Collectively, these results clearly supported sovleplenib as a therapeutic agent in the treatment of autoimmune diseases. Sovleplenib is being globally developed for ITP (Phase III, NCT05029635, Phase Ib/II, NCT03951623), wAIHA (Phase II/III, NCT05535933) and B-cell lymphoma (Phase I, NCT02857998, NCT03779113). Significance Statement Syk is a key mediator of signaling pathways downstream of a wide array of receptors important for immune functions, including the B cell receptor, immunoglobulin receptors bearing Fc receptors (FcRs). Inhibition of Syk could provide a novel therapeutic approach for autoimmune diseases and hematologic malignancies. The manuscript describes the preclinical pharmacology characterization of sovleplenib, a novel Syk inhibitor, in enzymatic and cellular assays in vitro and several murine autoimmune disease models in vivo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci的应助被不辣的皮特采纳,获得10
刚刚
lcsw发布了新的文献求助10
刚刚
刚刚
英俊的铭的应助被锂铂采纳,获得20
1秒前
酷波er的应助被sahjdkah采纳,获得10
1秒前
1秒前
檀江发布了新的文献求助10
2秒前
MonMon完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
卤蛋发布了新的文献求助10
3秒前
3秒前
3秒前
123发布了新的文献求助10
3秒前
dhy发布了新的文献求助10
3秒前
4秒前
4秒前
请赐我文献完成签到,获得积分10
4秒前
4秒前
粥粥完成签到,获得积分10
4秒前
4秒前
5秒前
莫断痕发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
5秒前
ob发布了新的文献求助10
5秒前
6秒前
思川完成签到,获得积分10
6秒前
6秒前
阿良发布了新的文献求助10
6秒前
L_YF发布了新的文献求助10
6秒前
zhang发布了新的文献求助10
6秒前
期刊的应助被潇洒的青柏采纳,获得10
6秒前
科目三的应助被111采纳,获得10
6秒前
酷波er的应助被777采纳,获得10
7秒前
8秒前
阿俞的应助被绵绵采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162621
求助须知:如何正确求助?哪些是违规求助? 9556889
关于积分的说明 21737583
捐赠科研通 7753002
什么是DOI,文献DOI怎么找? 3427836
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472507